That challenge, of finding or building good, useable data sets, is also one of the biggest differentiators in an increasingly ...

The annual conference of the Biotechnology Innovation Organization (BIO) is always an anticipated gathering where pharma and ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

The Inflation Reduction Act (IRA), signed into law in August 2022, marked a historic shift in US healthcare policy by ...

Liver damage is a well-recognised complication of gene therapies based on adeno-associated virus (AAV) vectors, and other ...

Streeting has also promised to reduce the time it takes to get clinical trials approved by cutting red tape, pointing out ...

Jeremy Skillington, CEO of LSE-listed Poolbeg Pharma, which has programmes targeting areas of high unmet medical need, ...

pharmaphorum is your source for news and analysis to stay on top of happenings in the world of pharma. Founded in 2009, pharmaphorum’s mission has always been to educate, inform, engage, and ...

New research reveals some significant imbalances between healthcare professionals' (HCP) demand and industry's provision of medical information, based on content types, channels and format.

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market ...